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Mutations in the gene that encodes the atypical channel-kinase
TRPM6 (transient receptor potential melastatin 6) cause HSH
(hypomagnesaemia with secondary hypocalcaemia), a disorder
characterized by defective intestinal Mg2 + transport and impaired
renal Mg2 + reabsorption. TRPM6, together with its homologue
TRPM7, are unique proteins as they combine an ion channel
domain with a C-terminally fused protein kinase domain. How
TRPM6 channel and kinase activity are linked is unknown.
Previous structural analysis revealed that TRPM7 possesses a
non-catalytic dimerization motif preceding the kinase domain.
This interacts with a dimerization pocket lying within the kinase
domain. In the present study, we provide evidence that the
dimerization motif in TRPM6 plays a critical role in regulating
kinase activity as well as ion channel activity. We identify
mutations within the TRPM6 dimerization motif (Leu1718 and
Leu1721) or dimerization pocket (L1743A, Q1832K, A1836N,
L1840A and L1919Q) that abolish dimerization and establish
that these mutations inhibit protein kinase activity. We also
demonstrate that kinase activity of a dimerization motif mutant
can be restored by addition of a peptide encompassing the
dimerization motif. Moreover, we observe that mutations that
disrupt the dimerization motif and dimerization pocket interaction
greatly diminish TRPM6 ion channel activity, in a manner that is
independent of kinase activity. Finally, we analyse the impact
on kinase activity of ten disease-causing missense mutations
that lie outwith the protein kinase domain of TRPM6. This
revealed that one mutation lying nearby the dimerization motif
(S1754N), found previously to inhibit channel activity, abolished
kinase activity. These results provide the first evidence that
there is structural co-ordination between channel and kinase
activity, which is mediated by the dimerization motif and pocket
interaction. We discuss that modulation of this interaction could
comprise a major regulatory mechanism by which TRPM6
function is controlled.
Key words: dimerization motif, hypomagnesaemia, ion channel,
phosphorylation, protein kinase, transient receptor potential
melastatin (TRPM).
INTRODUCTION
TRPM6 (transient receptor potential melastatin 6) is an
exceptional enzyme possessing a Mg2 + -permeant ion channel
domain and a C-terminal protein kinase moiety [1–4].
Autosomal recessive mutations in the TRPM6 gene cause HSH
(hypomagnesaemia with secondary hypocalcaemia), a serious
disorder that affects Mg2 + (re)absorption, resulting in decreased
serum Mg2 + levels [5,6]. This often manifests in convulsions
and spasms in early infancy, and can lead to tetany, seizures and
cardiac arrhythmias [7]. TRPM6 is specifically expressed in the
distal convoluted tubule of the kidney where it plays a prominent
role in maintaining blood Mg2 + levels (0.7–1.1 mM) [4,8,9].
Furthermore, the role of TRPM6 is emphasized by studies that
demonstrated embryonic lethality at mid-gestation (E12.5, where
E is embryonic day) in TRPM6-knockout mice due to inability to
control Mg2 + levels [10,11]. In contrast, its homologue TRPM7
is ubiquitously expressed in all cells and has been proposed to
play a general role in controlling cellular growth, survival and
proliferation [12–14], as well as cellular Mg2 + homoeostasis [15].
Consistent with this, knockout mutations in TRPM7 results in
early embryonic lethality before E7 [16]. To date, no mutations
in TRPM7 have been linked to human disease.
A critical question is how are the ion channel and catalytic
kinase domains regulated and whether the kinase domain is
responsible for controlling ion channel activity. Results to date
have failed to reveal a major functional link between the channel
and kinase activity as truncation of the kinase domain or kinase-
inactivating mutations in TRPM6 or TRPM7 do not disrupt
ion channel activity [17,18]. However, further more detailed
investigation has revealed that kinase truncations/inactivating
mutations may have a role in modulating ion channel gating
by Mg2 + ions, although the mechanism by which this occurs
is unclear [15,19–21]. The kinases of TRPM6 and TRPM7 share
a sequence homology of nearly 75%. Interestingly, the crystal
structure of the TRPM7 kinase domain has been resolved, and
the kinase domain was shown to assemble into a homodimer
[22]. This dimerization was mediated through a ∼30-residue α-
helical domain (which we term the ‘dimerization motif’) located
N-terminal to the kinase domain that binds to a region termed
the ‘dimerization pocket’ on the adjacent kinase domain [22,23].
These regions are situated on the intracellular C-terminal tail
of the protein. Mutation or truncation of the dimerization motif
in TRPM7 inhibits kinase activity [23], but how this affects
ion channel activity has not been studied. In the present study,
we have analysed in more detail the role that the TRPM6
dimerization motif plays in controlling kinase and channel
activities. We find that mutations in either the dimerization motif
or dimerization pocket ablate interaction and kinase activity.
Moreover, we demonstrate that these mutations markedly impair
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HSH, hypomagnesaemia with secondary hypocalcaemia; LDS, lithium dodecyl sulfate; MBP, myelin basic protein; TBST, TBS containing Tween 20; TRPM,
transient receptor potential melastatin.
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ion channel activity. We also show that the protein kinase activity
of a dimerization motif mutant can be restored by addition of
a dimerization motif peptide. Interestingly, catalytic screening
of previously described TRPM6 disease mutants led to the
identification of one missense mutation that results in kinase
inactivation. Altogether, these findings present new understanding
of the interrelationship between the TRPM6 kinase and channel
domains. We reveal how the kinase and channel are co-ordinately
activated and we discuss the possibility that conformational
change in the dimerization motif–dimerization pocket interface
plays a critical role in regulating TRPM6 function.
MATERIALS AND METHODS
Materials
Glutathione–Sepharose was from GE Healthcare. [γ 32P]ATP was
from PerkinElmer. Anti-FLAG M2–agarose, Tween 20, Colloidal
Coomassie Blue staining kit and pre-cast SDS/polyacrylamide
Bis-Tris gels were from Invitrogen. CHAPS was from
Calbiochem. Triton X-100 was from Sigma. Ampicillin was from
Merck. All peptides were synthesized by GL Biochem (Shanghai,
China).
General methods
Restriction enzyme digestions, DNA ligations and other recom-
binant DNA procedures were performed using standard protocols.
All mutagenesis was performed using the QuikChange®
site-directed mutagenesis method (Stratagene) with KOD
polymerase (Novagen). All DNA constructs were verified by
DNA sequencing, which was performed by The Sequencing
Service, School of Life Sciences, University of Dundee, using
DYEnamic ET terminator chemistry (GE Healthcare) on Applied
Biosystems automated DNA sequencers. DNA for mammalian
cell transfection was amplified in Escherichia coli DH5α strain
and plasmid preparation was carried out using Qiagen Maxiprep
Kit according to the manufacturer’s protocol.
Buffers
Lysis buffer for mammalian cell lysis contained 50 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 3%
(w/v) CHAPS, 1 mM sodium orthovanadate, 10 mM sodium
2-glycerophosphate, 50 mM sodium fluoride, 10 mM sodium
pyrophosphate, 0.27 M sucrose, 0.1% 2-mercaptoethanol, 1 mM
benzamidine and 0.1 mM PMSF. Lysis buffer for E. coli protein
purification contained 50 mM Tris/HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 1 mM
sodium orthovanadate, 10 mM sodium 2-glycerophosphate,
50 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.27 M
sucrose, 0.1% 2-mercaptoethanol, 1 mM benzamidine and
0.1 mM PMSF. Buffer A contained 50 mM Tris/HCl (pH 7.5)
and 0.1 mM EGTA. TBST (TBS containing Tween 20)
consisted of Tris/HCl (pH 7.5), 0.15 M NaCl and 0.2% Tween
20. SDS sample buffer was 1× NuPAGE LDS (lithium
dodecyl sulfate) sample buffer (Invitrogen), containing 1%
(v/v) 2-mercaptoethanol. Homogenization buffer for cellular
fractionation contained 50 mM Tris/HCl (pH 7.5), 10 mM KCl,
1.5 mM MgCl2, 0.1 mM EDTA, 0.5 mM EGTA and 44 mM
sucrose. RIPA buffer contained 50 mM Tris/HCl (pH 7.5),
150 mM NaCl, 0.1%SDS, 0.5% sodium deoxycholate, 1% (v/v)
Triton X-100, 0.1% 2-mercaptoethanol, 1 mM benzamidine and
0.1 mM PMSF.
Cell culture and transfections
HEK (human embryonic kidney)-293 cells were cultured
on 10-cm-diameter dishes in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin.
For transfection, each dish of adherent cells was transfected
with 5–10 μg of plasmid DNA and 20 μl of 1 mg/ml
polyethyleneimine (Polysciences) as described previously [24].
The cells were cultured for a further 48 h and lysed in 0.3 ml of ice-
cold lysis buffer per dish, lysates were clarified by centrifugation
at 26000 g at 4 ◦C for 15 min, and the supernatants were frozen in
500 μl aliquots in liquid nitrogen and stored at − 20 ◦C. Protein
concentrations were determined using the Bradford method.
Antibodies
The anti-(total GST) antibody was raised in sheep and affinity-
purified on the appropriate antigen. The anti-FLAG antibody
(F1804) was purchased from Sigma–Aldrich and the anti-GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) antibody (ab8245)
was purchased from Abcam. Secondary antibodies coupled to
HRP (horseradish peroxidase) used for immunoblotting were
obtained from Pierce. The anti-Na+ /K+ -ATPase antibody was
purchased from Cell Signaling Technology.
Expression and purification of TRPM6 truncates in E. coli
DNA for bacterial protein expression was transformed into E. coli
BL21 cells (Stratagene) and 0.5 litre cultures were grown at 37 ◦C
in LB broth containing 100 μg/ml ampicillin until the attenuance
at 600 nm was 0.8–1.0. IPTG (250 μM) was added and the cells
were cultured for a further 4 h at 37 ◦C. Cells were isolated by
centrifugation at 3500 g for 30 min and lysed in 25 ml of ice-cold
lysis buffer by sonication. Lysates were clarified by centrifugation
at 26000 g for 30 min at 4 ◦C followed by incubation with 0.5 ml
of glutathione–Sepharose for 1 h at 4 ◦C. The resin was washed
thoroughly and proteins were eluted in buffer A containing 0.27 M
sucrose and 20 mM glutathione.
Immunoprecipitation
For immunoprecipitation of FLAG and GST, FLAG M2–
agarose beads and glutathione–Sepharose were used respectively.
Lysates (0.5–5 mg) were incubated with 10–20 μl of antibody–
resin conjugate for 2 h at 4 ◦C with gentle agitation, and the
immunoprecipitates were washed three times with lysis buffer
containing 0.15 M NaCl and then twice with buffer A. Proteins
were eluted by resuspending washed immunoprecipitates in 30 μl
of SDS sample buffer.
Immunoblotting
Cell lysates (20 μg), purified proteins or immunoprecipitates
in SDS sample buffer were subjected to electrophoresis on
a polyacrylamide gel and transferred on to nitrocellulose
membranes. The membranes were incubated for 30 min with
TBST containing 5% (w/v) non-fat dried skimmed milk powder.
The membranes were immunoblotted in the same buffer overnight
at 4 ◦C with the indicated primary antibodies. Sheep antibodies
were used at a concentration of 1–2 μg/ml, whereas commercial
antibodies were diluted 1000–5000-fold. The blots were then
washed with TBST and incubated for 1 h at room temperature
(20 ◦C) with HRP-conjugated secondary antibodies diluted
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2500-fold in 5% (w/v) non-fat dried skimmed milk in TBST.
After repeated washes, the signal was detected with the ECL
reagent (GE Healthcare) and the X-ray films were processed in a
Konica Minolta Medical SRX-101 film processor.
Kinase assays
In assays using E. coli-expressed TRPM6, reactions were set up
in a volume of 20 μl, with substrate MBP (myelin basic protein)
at 1 μg and kinase at 0.1–10 μg in buffer A containing 0.1% 2-
mercaptoethanol, 10 mM MgCl2 and 0.1 mM [γ -32P]ATP (∼1000
cpm·pmol− 1). Assays were carried out for 30 min at 30 ◦C with
shaking at 1000 rev./min and terminated by addition of SDS
sample buffer. In mammalian HEK-293 immunoprecipitation
kinase assays, FLAG-tagged or GST-tagged wild-type and mutant
TRPM6 was immunoprecipitated from 1–3 mg of cell lysate
followed by addition of a reaction volume of 20 μl consisting
of buffer containing 0.1% 2-mercaptoethanol, 10 mM MgCl2
and 0.1 mM [γ -32P]ATP (∼1000 cpm·pmol− 1), with 1 μg of
MBP as substrate. Assays were carried out for 30 min at
30 ◦C with shaking at 100 g and terminated by the addition
of SDS sample buffer. For all assays, reaction mixtures were
resolved by SDS/PAGE. Proteins were detected by Coomassie
Blue staining and gels were imaged using an Epson scanner
and dried completely using a gel dryer (Bio-Rad Laboratories).
Incorporation of [γ -32P]ATP into substrates was analysed by
autoradiography using Hyperfilm (GE Healthcare) or quantified
by Cerenkov counting.
Peptide pull-down assays
The peptides biotin-C6-LKSPQEPHHHYSAIERNNLMRLSQ-
TIPFTPVQLFAGEEITV (wild-type) and biotin-C6-LKSPQE-
PHHHYSAIERNNAMRASQTIPFTPVQLFAGEEITV (mutant)
were purchased from GL Biochem. For a peptide pull-down, 1–
5 mg of lysate was incubated with 3 μg of the respective peptide
for 10 min at 4 ◦C under gentle agitation, followed by 5 min
of incubation with 10–20 μl of streptavidin beads at 4 ◦C. The
immunoprecipitates were washed three times with lysis buffer
containing 0.15 M NaCl and then twice with buffer A. Proteins
were eluted by resuspending washed immunoprecipitates in 30 μl
of SDS sample buffer.
PheraStar fluorescence polarization assay
The peptides used for the assay contained a C-terminal linker
leading to the peptides LKSPQEPHHHYSAIERNNLM-
RLSQTIPFTPVQLFAGEEITVGGCCPGCC (wild-type) and
LKSPQEPHHHYSAIERNNAMRASQTIPFTPVQLFAGEE-
ITVGGCCPGCC (mutant). The peptides were labelled with
Lumio Green (Invitrogen) following the manufacturer’s protocol.
Fluorescence polarization measurements were performed at
room temperature in buffer containing 25 mM Tris/HCl (pH 7.5),
200 mM NaCl and 5 mM 2-mercaptoethanol. Binding assays
were performed by combining 100 nM labelled peptide with
increasing concentrations of TRPM6 kinase, in a total volume of
30 μl of buffer, and end-point polarization measurements were
made using the BMG PheraStar plate reader. The polarization
values were measured at an excitation wavelength of 485 nm
and an emission wavelength of 538 nm, and were corrected for
fluorescent probe alone. At least ten data points were measured
for each curve, and each data point was measured in duplicate.
Data were analysed using GraphPad Prism 5 and curve-fitting
of the data from two independent experiments was performed
with one-site specific binding with Hill slope [model Y =
BmaxXh/(Kdh + Xh)] to determine Kd values.
Cellular fractionation
HEK-293 cells transfected with FLAG-tagged wild-type and
mutant TRPM6 were washed once with PBS and scraped into
PBS. The cell lysates were centrifuged at 500 g for 5 min and the
pellet was resuspended in homogenization buffer. Cells were lysed
by passing through a tight-fitting Dounce homogenizer 50 times
followed by centrifugation at 4000 g for 10 min. The supernatant
was centrifuged at 100000 g for 1 h in a Beckman type 90Ti rotor.
The pellet was resuspended in RIPA buffer and passed five times
through a 25-gauge needle. The supernatant was concentrated
using an ultraspin column with a membrane with a molecular
mass cut-off of 10 kDa. Membrane and cytoplasmic fractions
were prepared for immunoblots of FLAG and marker proteins.
Electrophysiology
Electrophysiological recordings were performed as described
previously [4]. Briefly, whole-cell currents were determined in
whole-cell configuration using an EPC-9 patch-clamp amplifier
controlled by the Patchmaster software (HEKA). Cells were
kept in an extracellular bath solution (150 mM NaCl, 10 mM
Hepes/NaOH and 1 mM CaCl2, pH 7.4). Electrode resistances
were between 2 and 3 M when filled with the pipette solution
(150 mM NaCl, 10 mM sodium EDTA and 10 mM Hepes/NaOH,
pH 7.2). A linear 500 ms voltage ramp from − 100 to + 100 mV
was applied every 2 s from a holding potential of 0 mV.
Current densities were determined by normalizing the current
amplitude obtained at + 80 mV 200 s after break in to the cell
membrane capacitance. All experiments were performed at room
temperature.
Mapping of phosphorylation site in the dimerization peptide
A kinase reaction was set up in a volume of 20 μl, with the wild-
type biotinylated dimerization peptide and the active (residues
1700–end) kinase fragment in buffer A containing 0.1% 2-
mercaptoethanol, 10 mM MgCl2 and 0.1 mM [γ -32P]ATP (∼1000
cpm·pmol− 1). Assays were carried out for 30 min at 30 ◦C with
shaking at 100 g The reaction was terminated by the addition
of LDS sample buffer. DTT was added to a final concentration
of 10 mM, the samples were boiled, then alkylated with 50 mM
iodoacetamide and subsequently resolved by a Bis-Tris 4–12%
polyacrylamide gel, which was stained with Colloidal Coomassie
Blue. The phosphorylated dimerization peptide band was excised,
cut into smaller pieces and washed sequentially for 10 min on a
vibrating platform with 1 ml of each of the following: water, a
1:1 (v/v) mixture of water and acetonitrile, 0.1 M ammonium
bicarbonate, a 1:1 mixture of 0.1 M ammonium bicarbonate and
acetonitrile, and finally acetonitrile. The gel pieces were dried
before incubation at 30 ◦C for 16 h in 25 mM triethylammonium
bicarbonate containing 5 g/ml trypsin as described previously
[24a]. Following tryptic digestion, more than 95% of the 32P
radioactivity incorporated in the gel bands was recovered, and
the samples were chromatographed on a Vydac 218TP5215 C18
column (Separations Group) equilibrated in 0.1% trifluoroacetic
acid in water. The column was developed with a linear
acetonitrile gradient at a flow rate of 0.2 ml/min and fractions
of 0.1 ml were collected and analysed for 32P radioactivity by
Cerenkov counting. Isolated phosphopeptides were analysed by
MS analysis as follows. LC–MS/MS was performed using a
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linear ion trap–orbitrap hybrid mass spectrometer (OrbiTrap
Classic) equipped with a nanoelectrospray ion source (Proxeon
Biosystems or Thermo) and coupled to a Proxeon EASY-nLC
system. Peptides were typically injected on to a Thermo/Dionex
Acclaim PepMap100 reverse-phase C18 column, 75 m×15 cm,
with a flow rate of 300 nl/min and eluted with a 40 min linear
gradient of 95% solvent A (2% acetonitrile and 0.1% formic
acid in water) to 35% solvent B (90% acetonitrile and 0.08%
formic acid in water). The instrument was operated with the ‘lock
mass’ option to improve the mass accuracy of precursor ions, and
data were acquired in the data-dependent mode, automatically
switching between MS and MS/MS acquisition. Full-scan spectra
(m/z 340–1800) were acquired in the orbitrap with resolution
R = 60000 at m/z 400 (after accumulation to a target value
of 1000000). The five most intense ions, above a specified
minimum signal threshold, based on a low-resolution (R = 20000)
preview of the survey scan, were fragmented by collision-induced
dissociation and recorded in the linear ion trap (target value
of 5000). Multistage activation was used to provide an MS3
scan of parent ions showing a neutral loss of 48.9885, 32.6570
and 24.4942, allowing for 2+ , 3+ and 4+ ions respectively.
The resulting MS3 scan was automatically combined with the
relevant MS/MS scan before data analysis using the Mascot search
algorithm (http://www.matrixscience.com) run on a local server.
32P-labelled phosphopeptide sequence analysis
The site of phosphorylation of the 32P-labelled peptides was
determined by solid-phase Edman degradation, on an Applied
Biosystems 494C sequencer, of the peptide coupled to Sequelon-
AA membrane (Applied Biosystems) as described previously
[25].
RESULTS
The TRPM6 dimerization domain is critical for kinase activity
Previous studies have focused on monitoring TRPM7
kinase activity by measuring its autophosphorylation and
phosphorylation of the exogenous substrate MBP [2,3,26].
To analyse the TRPM6 kinase activity, we first expressed
in HEK-293 cells full-length wild-type TRPM6 as well as
a catalytically inactive TRPM6 mutant in which the kinase
catalytic lysine residue is replaced by arginine (K1804R), which
has been reported previously to abolish autophosphorylation
[17]. Immunoprecipitation of the full-length protein confirmed
that TRPM6 undergoes autophosphorylation and is able to
phosphorylate MBP in a manner that is ablated by the kinase-
inactivating mutation (Figure 1B).
Structural analysis of the kinase domain of TRPM7
revealed that it contained a non-catalytic N-terminal extension
encompassing a ∼30-residue α-helical region, which mediates
dimerization and we therefore termed this the ‘dimerization
motif’ [22]. The dimerization motif is highly conserved in
TRPM6 and corresponds to residues 1700–1730 in human
TRPM6 (Figure 1A). To explore the role of the dimerization
motif in TRPM6, we expressed in HEK-293 cells fragments that
encompass [TRPM6-(1700–end)] or lack [TRPM6-(1730–end)]
this motif. This revealed that TRPM6-(1700–end) containing
the dimerization motif displayed significant catalytic MBP as
well as autophosphorylation activity that is abolished by the
K1804R mutation (Figure 1B). In contrast, TRPM6-(1730–end)
lacking the dimerization motif displayed no MPB kinase or
autophosphorylation activity (Figure 1B). We also expressed
these catalytic fragments of TRPM6 in E. coli and observed
that TRPM6-(1700–end) was active and TRPM6-(1730–end)
displayed no activity, even at high concentrations (Figure 1C).
To establish which residues in the dimerization motif were
critical for kinase activity, we undertook an alanine scan of
each of the amino acids in the 1700–1730 region and delineated
how individual mutations affected kinase activity of TRPM6-
(1700–end). This revealed that mutation of two highly conserved
leucine residues (Leu1718 and Leu1721) led to a significant loss in
kinase activity, whereas the other mutations had little or no effect
(Figure 1D).
The dimerization domain directly binds to and activates TRPM6
kinase
Closer inspection of the TRPM7 dimeric kinase domain structure
revealed that the dimerization motif forms an extended α-
helix which undergoes extensive interactions with a region
in the kinase domain of the other monomer termed the
‘dimerization pocket’ [22] (Figure 2A). We next utilized
fluorescence polarization technology, a sensitive method to
evaluate interactions between proteins and peptides [27]. Using
this methodology, we first evaluated how polarization of a
fluorescently labelled peptide encompassing the dimerization
motif was affected by titration of TRPM6-(1730–end) (which
lacks the dimerization motif). This revealed a dose-dependent
increase in fluorescence polarization following addition of
increasing concentrations of TRPM6-(1730–end) (Figure 2B),
which indicates binding. Kinetic analysis of the data demonstrated
that interaction data could be fitted using a variable slope
model to a one-site-binding equation (Hill slope of 1.0), with
Kd calculated as 0.7 μM (Kd 0.713 μM). In contrast, when
analysis was undertaken with a mutant dimerization motif peptide
containing the two leucine mutations (L1718A + L1721A) that
impaired TRPM6 catalytic activity (Figure 1D), only background
increases in fluorescence polarization were observed (Figure 2B).
Next, we addressed whether it was possible to affinity-
purify TRPM6-(1730–end) from HEK-293 cell extracts by
employing a biotinylated dimerization motif peptide conjugated
to streptavidin–Sepharose. We found that this peptide, but not the
mutant (L1718A + L1721A), could efficiently purify TRPM6-
(1730–end) (Figure 2C).
We next investigated whether this binding of the dimerization
motif peptide could restore catalytic activity of the inactive
TRPM6-(1730–end) fragment. Addition of the dimerization motif
peptide resulted in a dose-dependent activation of TRPM6-(1730–
end) with half-maximal activation observed at ∼15 μM peptide
(Figure 2D). In contrast, concentrations of as high as 100 μM
mutant (L1718A + L1721A) peptide failed to significantly
activate TRPM6-(1730–end). We observed that the specific
activity of TRPM6-(1730–end) incubated with 30 μM peptide
corresponded to approximately half of the specific kinase activity
of the TRPM6-(1700–end) fragment containing the dimerization
motif (Figure 2E). Addition of the dimerization motif peptide did
not enhance the kinase activity of TRPM6-(1700–end) further
(Figure 2E).
Our data suggest that the TRPM6 dimerization motif binds
and activates the kinase domain with Leu1718 and Leu1721
playing a critical role. If this model is correct, we would
predict that the full-length tetrameric TRPM6 protein functions
through dimerization, and thereby each monomeric dimerization
motif would occupy the dimerization pocket of its adjacent
kinase domain, leaving no scope to bind the dimerization
motif peptide in trans. Consistent with this, we find that
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Figure 1 Characterization of TRPM6 (auto)phosphorylation in C-terminal truncation mutants
(A) Schematic representation of the domain structure of TRPM6 demonstrating the ion channel domain and the α-kinase domain. The lower panel demonstrates a multiple sequence alignment of the
1700–1730 region of TRPM6 among different species along with human TRPM7. Asterisks represent conserved amino acids. (B) The Coomassie Blue-stained SDS gel indicates the FLAG-tagged
full-length and truncated forms of wild-type and kinase-inactive (KI) TRPM6. Phosphorylation of MBP and TRPM6 itself was determined by autoradiography (lower panels). (C) Increasing amounts
of GST-purified kinase fragments TRPM6-(1700–end) and TRPM6-(1730–end) were subjected to a kinase assay using MBP as substrate. Proteins were separated by SDS/PAGE, stained with
Coomassie Blue (top and middle panels) and phosphorylation was detected by autoradiography (bottom panel). (D) Alanine-scanning mutagenesis has been performed on the 1700–1730 region.
The indicated GST-tagged mutants were immunoprecipitated from overexpressed HEK-293 cells, and kinase activity was assayed using MBP as substrate. Proteins were separated by SDS/PAGE,
stained with Coomassie Blue (top and middle panels) and phosphorylation was detected by autoradiography (bottom panel). Molecular masses are indicated in kDa.
full-length wild-type and kinase-inactive TRPM6 expressed
in HEK-293 cells do not interact with the biotinylated
dimerization motif peptide conjugated to streptavidin–Sepharose
(Figure 2F). In contrast, full-length TRPM6 mutants in which
the dimerization pocket would be unoccupied as a result of
L1718A + L1721A mutations is rendered capable of interacting
with the biotinylated dimerization motif peptide conjugated to
streptavidin–Sepharose (Figure 2F). We also demonstrated that
individual or double L1718A and L1721A mutations ablated
kinase activity in full-length TRPM6, confirming the importance
of this dimerization motif interaction in regulating kinase activity
(Figure 2G).
Identification of critical residues in the TRPM6 dimerization pocket
The critical dimerization motif residues Leu1718 and Leu1721 are
conserved in TRPM7 (Figure 1A), where the equivalent Leu1561
and Leu1564 make several hydrophobic interactions with four
kinase domain residues (Gln1674, Ala1678, Leu1681 and Leu1761) and a
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://portlandpress.com
/biochem
j/article-pdf/460/2/165/679271/bj4600165.pdf by R
adboud U
niversiteit N
ijm
egen user on 23 D
ecem
ber 2019
170 J. van der Wijst and others
Figure 2 Identification of dimerization motif residues in TRPM6
(A) Structural model of TRPM7 α-kinase depicting the N-terminal non-catalytic α-helix of one monomer that interacts with the kinase segment of the other monomer. (B) Fluorescence polarization
analysis of wild-type (WT) and mutant (Mut) dimerization motif peptides with E. coli-purified GST-tagged TRPM6-(1730–end). (C) GST-tagged TRPM6-(1730–end) was expressed in HEK-293 cells,
and lysates were subjected to a peptide pull-down, as described in the Materials and methods section, using either wild-type (WT) or mutant (Mut) dimerization motif peptide. The samples were
analysed by immunoblotting with anti-GST antibody (top panel). Total cell extracts were immunoblotted with GST antibody (middle panel), using GAPDH expression as loading control (bottom
panel). (D) Immunoprecipitation of FLAG-tagged TRPM6-(1730–end) wild-type and kinase-inactive TRPM6 from HEK-293 cell lysate was followed by a kinase assay using increasing concentrations
of the wild-type (WT) dimerization motif peptide, and highest concentrations (100 μM) for mutant (Mut) peptide. Proteins were separated by SDS/PAGE, stained with Coomassie Blue (top and
middle gels) and MBP phosphorylation was detected by autoradiography (bottom gel). Incorporated radioactive counts are depicted as a histogram. (E) FLAG-tagged TRPM6-(1730–end) and
TRPM6-(1700–end), both wild-type and kinase-inactive (KI) were immunoprecipitated and subjected to a kinase assay without ( − ) or with ( + ) 30 μM dimerization motif peptide. Proteins were
separated by SDS/PAGE, stained with Coomassie Blue (top and middle gels) and MBP phosphorylation was detected by autoradiography (bottom gel). Incorporated radioactive counts are depicted
as a histogram. (F) Full-length FLAG-tagged TRPM6 wild-type, kinase-inactive (KI) and indicated mutants from HEK-293 cells lysate were subjected to a peptide pull-down, as described in the
Materials and methods section, using the wild-type dimerization motif peptide. The pull-down samples were analysed by immunoblotting with anti-FLAG antibody (top panel). Total cell extracts
were immunoblotted with anti-FLAG antibody (middle panel), using GAPDH expression as loading control (bottom panel). (G) Immunoprecipitated FLAG-tagged TRPM6 and indicated mutants
were subjected to a kinase assay using MBP as substrate. Proteins were separated by SDS/PAGE, stained with Coomassie Blue (top and middle panels) and MBP phosphorylation was detected by
autoradiography (bottom panel). Molecular masses are indicated in kDa.
non-catalytic N-terminal residue (Leu1585) within the dimerization
pocket (Figure 3A). Interestingly, the equivalent four catalytic
residues (Gln1832, Ala1836, Leu1840 and Leu1919) and the non-catalytic
residue (Leu1743) are conserved in TRPM6 (Supplementary Fig-
ure S1 at http://www.biochemj.org/bj/460/bj4600165add.htm).
To investigate the role that these residues play in enabling
binding of the dimerization motif, the TRPM6-(1730–end)
wild-type and dimerization pocket mutants (L1743A, Q1832K,
A1836N, L1840A and L1919Q) were expressed in HEK-293
cells and tested for their ability to bind to the biotinylated
dimerization motif peptide conjugated to streptavidin–Sepharose.
This revealed that individual mutation of all of these residues
abolished binding to the peptide (Figure 3B). Fluorescence
polarization binding assays confirmed that two of these mutations
(L1743A and L1919Q) inhibited interaction with the fluorescently
labelled dimerization motif peptide (Figure 3C). Consistent with
occupancy of the dimerization pocket being required for kinase
activity, we found that incorporating the dimerization pocket
mutations in either TRPM6-(1700–end) (Figure 3D) or full-
length TRPM6 (Figure 3F) abolished kinase activity. Finally, we
observed that the ability of the dimerization peptide to activate
TRPM6-(1730–end) was prevented by the L1743A and L1919Q
dimerization pocket mutations (Figure 3E).
Importance of dimerization binding for TRPM6 channel activity
Next, we examined whether binding of the dimerization motif
to the dimerization pocket in the kinase domain plays a role in
regulating TRPM6 channel function. To address this question,
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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Figure 3 Analysis of the dimerization pocket residues
(A) Structural model of TRPM6 based on TRPM7 α-kinase depicting the binding of Leu1718 and Leu1721 to other residues in the α-kinase domain. (B) GST-tagged TRPM6-(1730–end) and the
indicated mutants were expressed in HEK-293 cells. Subsequently, cell lysate was subjected to a peptide pull-down, as described in the Materials and methods section, using wild-type dimerization
motif peptide. The samples were analysed by immunoblotting with anti-GST antibody (top panel). Total cell extracts were immunoblotted with anti-GST antibody (middle panel), using GAPDH
expression as loading control (bottom panel). (C) Fluorescence polarization analysis of the dimerization motif peptide with E. coli purified GST-tagged TRPM6-(1730–end) and indicated mutants.
(D) Immunoprecipitation of GST-tagged TRPM6-(1700–end) and indicated mutants from HEK-293 cell lysate was followed by a kinase assay. Proteins were separated by SDS/PAGE, stained with
Coomassie Blue (top and middle panels) and MBP phosphorylation was detected by autoradiography (bottom panel). (E) GST-tagged TRPM6-(1730–end), both wild-type and kinase-inactive (KI),
and L1743A and L1919Q mutants were expressed in HEK-293 cells, followed by immunoprecipitation and then subjected to a kinase assay without ( − ) or with ( + ) 30 μM dimerization motif
peptide. Proteins were separated by SDS/PAGE, stained with Coomassie Blue (top and middle gels) and MBP phosphorylation was detected by autoradiography (bottom gel). Incorporated radioactive
counts are depicted as a histogram. (F) Immunoprecipitated FLAG-tagged TRPM6 and the indicated mutants were subjected to a kinase assay using MBP as substrate. Proteins were separated by
SDS/PAGE, stained with Coomassie Blue (top and middle panels) and MBP phosphorylation was detected by autoradiography (bottom panel). Molecular masses are indicated in kDa.
full-length wild-type TRPM6, and kinase-inactive (K1804R),
dimerization motif (L1718A, L1721A and L1718A + L1721A)
and dimerization pocket (L1743A and L1919Q) mutants were
expressed in HEK-293 cells and we studied channel activity by
whole-cell patch-clamp recordings. TRPM6 is a constitutively
active cation channel that is tightly regulated by intracellular
Mg2 + and Mg2 + -ATP. Therefore TRPM6 currents are induced
by internal Mg2 + depletion using Mg2 + -free pipette solutions
containing EDTA. TRPM6 channels produce small inward
currents at physiological negative membrane potentials and
distinct outward rectification at positive membrane potentials
(Figures 4A and 4B). Consistent with previous studies, the
kinase-inactive TRPM6 has a similar current–voltage relationship
(Figure 4A) and amplitude (Figure 4B) as wild-type. Interestingly,
however, the dimerization motif mutants displayed significant
(∼3-fold) diminished current amplitudes (Figures 4A and 4B). We
also observed that the current activity of the TRPM6 dimerization
pocket mutants was significantly reduced (Figures 4C and 4D).
As a control, we demonstrated that the membrane expression of
the dimerization motif and dimerization pocket mutants was equal
to that of the wild-type and kinase-inactive TRPM6, suggesting
that these mutations do not hamper expression and transport
to the plasma membrane (Figure 4E). Furthermore, we have
demonstrated that mutation of the dimerization motif or pocket
residues in kinase-inactive TRPM6 also significantly reduce
the current amplitudes. This provides further evidence that the
mechanism by which dimerization stimulates TRPM6 ion channel
activity is independent of kinase activity (Figure 4F).
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Figure 4 Dimerization interactions are linked to the channel function
(A) Representative current recorded after 200 s of stimulation by a voltage ramp between − 100 and + 100 mV of HEK-293 cells transfected with wild-type and kinase-inactive (KI) TRPM6 and
the indicated mutants (L1718A, L1721A and L1718/21AA). (B) Histogram summarizing the current density (pA/pF) at + 80 mV of TRPM6 and indicated mutants. **P < 0.05 and ***P < 0.01
compared with wild-type TRPM6 (n = 11–50 cells). (C) Representative current recorded after 200 s of stimulation by a voltage ramp between − 100 and + 100 mV of HEK-293 cells transfected with
TRPM6 and the indicated mutants (L1743A and L1919Q). (D) Histogram summarizing the current density (pA/pF) at + 80 mV of TRPM6 and the indicated mutants. **P < 0.05 and ***P < 0.01
compared with wild-type TRPM6 (n = 11–50 cells). (E) Membrane and cytoplasmic fractions were obtained by ultracentrifugation to determine the expression of FLAG-tagged TRPM6 and all
mutants. Lysates were immunoblotted with anti-FLAG antibody, and Na+ /K+ -ATPase and GAPDHs used as membrane and cytosolic marker were respectively. Molecular masses are indicated in
kDa. (F) Histogram summarizing the current density (pA/pF) at + 80 mV of kinase-inactive (KI) TRPM6 and indicated double mutants (KI + L1718A, KI + L1721A, KI + L1743A and KI + L1919Q).
**P < 0.05 compared with TRPM6 KI (n = 13–25 cells). Results are means +− S.E.M.
Impact on kinase activity of disease-causing missense mutations
In addition to a number of frameshift mutations, ten missense
mutations in TRPM6 have been identified that cause HSH
[5,6,28]. These are all located outside the catalytic domain
(Figure 5A). Interestingly one of the residues, Ser1754, lies just
before the kinase domain and inspection of the equivalent residue
in the TRPM7 structure suggests that is located in close proximity
to the dimerization motif–dimerization pocket interaction. To
screen the effects that the missense mutations have on TRPM6
activity, we expressed full-length TRPM6 wild-type, kinase-
inactive and all ten mutants in HEK-293 cells and assessed
kinase activity after immunoprecipitation. All TRPM6 mutants
were expressed at equal levels to that of wild-type and displayed
similar kinase activity, except for S1754N which was catalytically
inactive (Figure 5B). Parallel to the other dimerization
pocket mutants analysed in the present study (L1743A and
L1919Q, Figure 4D), a recent study has shown that the
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Figure 5 The disease-causing mutation S1754N also abrogates kinase function in TRPM6
(A) Schematic representation of the domain structure of TRPM6 depicting the missense mutations identified in patients suffering from HSH. (B) Immunoprecipitated FLAG-tagged wild-type and
kinase-inactive (KI) TRPM6 and indicated mutants were subjected to a kinase assay using MBP as substrate. Proteins were separated by SDS/PAGE, stained with Coomassie Blue (top and middle
panels) and MBP phosphorylation was detected by autoradiography (bottom panel). Molecular masses are indicated in kDa.
S1754N mutant also displays markedly reduced channel activity
[28].
DISCUSSION
TRPM6, together with its homologue TRPM7, are unique as they
are the only known examples in Nature that consist of both an
ion channel and a kinase domain within the same polypeptide
chain. Before the present study, the mechanism by which channel
and kinase activity were co-ordinated was unknown. The main
conclusion of the present study is demonstrating for the first
time a direct link between the kinase and channel function
of TRPM6. Our data reveal that binding of the dimerization
motif to the dimerization pocket is essential for both kinase and
ion channel activity. We identify critical residues required for
this interaction and demonstrate that mutation of these residues
leads to a significant suppression of both kinase and channel
activity. Significantly, we also characterized a HSH disease-
causing missense mutation, lying within the dimerization pocket–
dimerization motif interaction (S1754N), that inhibits kinase
(Figure 5C) as well as channel activity [28].
Each TRPM6 subunits comprises six transmembrane segments,
an intracellular N-terminal tail (∼800 residues) and an
intracellular C-terminal segment encompassing the kinase domain
(∼1000 residues). Previous studies indicated that TRPM6
operates as a tetramer in which the channel pore is built up
by the membrane-spanning regions of four TRPM6 subunits
[29,30]. The data suggest that in the channel and kinase-active
conformation, the dimerization motif of one subunit interacts
with a dimerization pocket of another subunit. The present study
proposes that all mutations that we have tested that abolish this
interaction also impair kinase as well as channel activity. The
present paper is the first report of individual mutations that disrupt
both catalytic activities of TRPM6 and strongly suggests that
channel activity is linked to kinase function.
It should be noted that the physiologically relevant regulation
of TRPM6 and TRPM7 channel activity is a controversial topic.
Previous studies have demonstrated that the kinase domain is
redundant for TRPM6 or TRPM7 channel function, but is involved
in the modulation of channel activity [15–18,21]. Intracellular
levels of Mg2 + or Mg2 + -ATP are important factors for controlling
TRPM6 and TRPM7 activity [4,12,19,21]. A recent study
provided support for the TRPM6 kinase domain as a Mg2 + /Mg2 + -
ATP-sensing mechanism regulating TRPM6/TRPM7 channel
activity [21]. Together with our results, this suggests that kinase
activity is not essential for the dimerization motif–dimerization
pocket interaction, which stimulates channel function. On the
contrary, it implies that the dimerization interactions provide
the basis for TRPM6 functioning. Advanced ways to study
TRPM6 in a more physiological context could provide further
answers on the regulatory mechanism for dimerization. Future
work towards optimizing Mg2 + -sensitive probes for TRPM6
channel measurements would greatly improve this.
Interestingly, TRPM7-deficient mice lacking the kinase domain
show early embryonic lethality, and embryonic stem cells from
these mice exhibit growth inhibition that can be restored by
Mg2 + supplementation [31], which points towards a physiological
importance of the kinase domain. These stem cells produce active
TRPM7 channels, albeit with reduced current magnitude [31].
This suggests that the channel adopts an active conformation
following truncation of the kinase domain. In future work,
it would be interesting to test how a knockin mutation
that ablated dimerization motif–dimerization pocket interaction
affected channel function. It would also be interesting to explore
how a knockin mutation that abolished TRPM6/TRPM7 kinase
function affected phenotype and channel activity.
It has been shown previously that TRPM6 can assemble
into complexes with TRPM7, at least in co-expression studies
[15,32]. Interestingly, it has been shown that TRPM6–TRPM7
complexes displayed different channel characteristics compared
with TRPM6 and TRPM7 alone [21,32]. As the sequence of
the dimerization motif (Figure 1A) and pocket (Supplementary
Figure S1) are highly conserved in TRPM6 and TRPM7, this
suggests that the dimerization motif of TRPM6 could interact
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with the dimerization pocket of TRPM7 and vice versa. It would
be interesting to see whether this cross-dimerization contributes
to different channel characteristics observed and potentially some
of the dimerization motif and dimerization pocket mutants could
be utilized to study this.
In future work, it will be critical to explore whether
the physiological stimuli that regulate TRPM6 function do
so by influencing the dimerization motif–dimerization pocket
interaction. Another critical question will be to define what
are the physiological substrates of the TRPM6 kinase and how
phosphorylation of these proteins modulates downstream biology.
To date, the only clear-cut TRPM6 substrates identified are a
series of autophosphorylation sites lying between the kinase and
channel domains [17,26]. Interestingly, a recent study for in vivo
TRPM7 phosphorylation sites identified autophosphorylation of
two residues (Ser1565 and Ser1567) that are located within the
dimerization motif and are conserved in TRPM6 (Ser1722 and
Thr1724) [33]. We have been able to confirm that Thr1724 comprises
a major TRPM6 autophosphorylation site (Supplementary Figure
S2 at http://www.biochemj.org/bj/460/bj4600165add.htm). An
attractive hypothesis is that autophosphorylation of Thr1724
and potentially other residues could induce conformational
changes that modulate the dimerization motif–dimerization
pocket interaction and hence influence channel activity. So far,
we have mutated Thr1724 as well as a number of other TRPM6
phosphorylation sites that we have mapped (Ser1281, Ser1304, Ser1306,
Ser1329, Ser1365, Ser1560, Ser1562, Ser1563, Ser1658, Ser1685, Ser1689,
Ser1722, Thr2011 and Ser2015), but, to date, none of these had a
significant impact on kinase activity. We have also synthesized
a dimerization motif peptide phosphorylated at Thr1724, but
observed that this peptide interacted and activated TRPM6-(1730–
end) similarly to the non-phosphorylated dimerization motif
peptide (Supplementary Figure S2). Further work is required
to understand how phosphorylation of TRPM6 influences its
activity.
A key question concerns the mechanism by which channel
activity is disrupted by inhibiting the interaction of the
dimerization motif to the dimerization pocket on an adjacent
TRPM6 kinase domain. One possibility would be that the
dimerization motif or dimerization pocket could form an
inhibitory interaction with the N-terminal tail or channel domains.
As both the N-terminal and C-terminal non-transmembrane
regions are localized in the intracellular compartment, this offers
scope for potential interactions. In future work, it would be
interesting to explore whether such interactions can be observed
and defining how critical these are in regulating TRPM6. It
should be noted that none of the N-terminal or transmembrane-
located disease mutants we have analysed that inhibit channel
activity [28,34] affect kinase activity (Figure 5B). Furthermore,
it would also be of interest to undertake further analysis on the
large cytoplasmic N-terminal domain of TRPM6 that possesses
no obvious function, which might provide further clues to how
TRPM6 is regulated and functions.
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Kinase and channel activity of TRPM6 are co-ordinated by a dimerization
motif and pocket interaction
Jenny VAN DER WIJST*1, Maxime G. BLANCHARD†, Helen I. WOODROOF*, Thomas J. MACARTNEY*, Robert GOURLAY*,
Joost G. HOENDEROP†, Rene´ J. BINDELS† and Dario R. ALESSI*1
*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
†Department of Physiology, Radboud university medical center, 6500 HB Nijmegen, The Netherlands
Figure S1 Sequence alignment between human TRPM6 and mouse TRPM7
Conserved dimerization pocket motif residues (Leu1743, Gln1832, Ala1836, Leu1840 and Leu1919) are indicated by arrows.
1 Correspondence may be addressed to either of these authors (email jenny.vanderwijst@radboudumc.nl or d.r.alessi@dundee.ac.uk).
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Figure S2 Identification and characterization of phosphosite Thr1724 in the dimerization motif peptide
(A) Mapping of phosphopeptides on the dimerization motif peptide after phosphorylation by TRPM6 in vitro. GST-tagged TRPM6-(1700–end) was immunoprecipitated and subjected to a kinase
assay including the biotinylated dimerization peptide (500μM). Assays were terminated by addition of LDS loading buffer, and proteins were separated by SDS/PAGE. Proteins were detected by
Colloidal Coomassie Blue staining, and the stained phosphorylated dimerization motif peptide was digested with trypsin, followed by reverse-phase HPLC on a Vydac C18 column equilibrated with
0.1 % trifluoroacetic acid, and the column was developed with an acetonitrile gradient (broken line). The flow rate was 0.2 ml/min and fractions (0.1 ml each) were collected and analysed for 32P
radioactivity by Cerenkov counting. A major 32P-labelled peak was identified. (B) Solid-phase sequence analysis of the tryptic phosphopeptide RLSQT(p)IPFTPVQLFAGEEITV (residues 19–41).
The peptide was phosphorylated at threonine at position 22, corresponding to Thr1724 in TRPM6. (C) GST-tagged TRPM6-(1730–end) was expressed in HEK-293 cells, and lysates were subjected
to a peptide pull-down, as described in the Materials and methods section of the main text, using either wild-type (WT) or phospho-wild-type (WT-P) dimerization motif peptide. The samples
were analysed by immunoblotting with anti-GST antibody (top panel). Total cell extracts were immunoblotted with anti-GST antibody (middle panel), using GAPDH expression as loading control
(bottom panel). (D) GST-tagged TRPM6-(1730–end) was expressed in HEK-293 cells, followed by immunoprecipitation and subjected to a kinase assay using 30μM of either wild-type (WT) or
phospho-wild-type (WT-P) dimerization motif peptide. Proteins were separated by SDS/PAGE, stained with Coomassie Blue, and MBP phosphorylation as well as peptide phosphorylation were
detected by autoradiography. Molecular masses are indicated in kDa.
Received 13 December 2013/28 February 2014; accepted 21 March 2014
Published as BJ Immediate Publication 21 March 2014, doi:10.1042/BJ20131639
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://portlandpress.com
/biochem
j/article-pdf/460/2/165/679271/bj4600165.pdf by R
adboud U
niversiteit N
ijm
egen user on 23 D
ecem
ber 2019
